Scientific Programs

Proliferating cell nuclear antigen (PCNA) is an important protein necessary for the repair of DNA in cells. Cancer cells express a unique type of PCNA (termed caPCNA) which is only found at small quantities in non-cancer cells.

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

Pneumonia (infection in the lungs) is a common diagnosis in dogs and cats and can be caused by a variety of pathogens (i.e., bacteria, viruses, fungal organisms). Collecting fluid samples from the lungs of patients with pneumonia allows for tests to be performed that can identify the organism causing the infection.

The intestinal microbiota are highly functional, with a combined genome (termed the microbiome) that is approximately 130-160 times larger than the human or canine genome. The microbiome is a highly functional organ and produces approximately 1,000 different metabolites, many of which have systemic effects in the dog. Intestinal dysbiosis is defined as an alteration in

Sepsis is caused by a severe infection that enters the bloodstream and is associated with a high mortality rate. This high mortality rate has remained unchanged over the last three decades even though there has been active research in the area.

Following removal of the primary tumor and adjuvant chemotherapy, the development of lung metastasis is the most common cause of mortality in dogs with osteosarcoma. A distinctive feature of lung metastases of osteosarcoma in human patients is the surprising benefit that can result from surgical resection of the lung nodules. The use of surgery to

Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second drug, Encequidar, which improves this issue of poor

We propose that the spontaneous, but strongly genetic-based model of canine Necrotizing meningoencephalitis (NME) presents a unique way to help demonstrate the feasibility of inflammatory neurological disease prevention therapy.

Neutropenia (low white blood cell count) is a common side effect of chemotherapy in patients with cancer, with sepsis being a potential consequence. The timely identification and treatment of sepsis is paramount to the success of therapy.

Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival.

This study is looking to evaluate the pharmacology profile of CBD in dogs (i.e. how it’s processed in the body) as well as its effectiveness in treating pain in dogs with chronic osteoarthritis. This study will hopefully result in similar studies being conducted in the fields of Neurology and Oncology.

Based on its reported tolerability in dogs (alone and in combination with chemotherapy) this study will ask whether Rapamycin may improve treatment outcomes for dogs with hemangiosarcoma, and more precisely, to understand the hemangiosarcoma genotypes which may most benefit from its use.